Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: 1. Obesity Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

NCT04175678
View directory record Official record
Conditions
Healthy Lifestyle, Obese, Men
Interventions
Diet, Exercise, Standard care
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment

NCT01099618
View directory record Official record
Conditions
Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia
Interventions
metformin, placebo, Sitagliptin
Drug
Lead sponsor
Dawn Smiley MD
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055
View directory record Official record
Conditions
Weight Loss
Interventions
Placebo, VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 29, 2026, 1:37 PM EDT
Recruiting Phase 1 Interventional

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

NCT07673900
View directory record Official record
Conditions
Overweight and/or Obesity
Interventions
VX-201, semaglutide SC
Combination Product · Drug
Lead sponsor
Terrestrial Bio, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

NCT07594093
View directory record Official record
Conditions
Overweight or Obesity
Interventions
REGN20934, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

UCSD Get Fit, Be Fit Study

NCT03387709
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Pistachio-enriched diet, General dietary guidance diet
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT06525935
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

NCT05296733
View directory record Official record
Conditions
Healthy, Liver Diseases, Obesity
Interventions
BI 456906
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips

NCT05574049
View directory record Official record
Conditions
Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia
Interventions
Tetrahydrocannabivarin, Placebo
Drug · Other
Lead sponsor
Medical Life Care Planners, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 3 Interventional

State-wide Health Approach to Increase Reach and Effectiveness: Study 1

NCT01264393
View directory record Official record
Conditions
Obesity
Interventions
Shape Up Rhode Island + Online Resources, Shape Up Rhode Island + Online Weight Loss Program, Shape Up Rhode Island + Online Weight Loss Program + Group sessions
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity

NCT07717814
View directory record Official record
Conditions
Overweight and Obesity
Interventions
AMG 133 (frozen liquid), AMG 133 (liquid)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

NCT05677867
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

NCT05745701
View directory record Official record
Conditions
Healthy
Interventions
PF-07081532, Cyclosporine, Itraconazole
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 29, 2026, 1:37 PM EDT
Withdrawn Phase 2 Interventional

Study the Relationship Between Obesity and Hepatitis C Replication

NCT01157975
View directory record Official record
Conditions
Hepatitis C
Interventions
Pioglitazone, Prednisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Buy 1 Get 1: Role of Grocery Coupons in Promoting Obesogenic Home Food Environments and Eating Behaviors

NCT01710124
View directory record Official record
Conditions
Obesity
Interventions
Financial incentives
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 29, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children

NCT05464186
View directory record Official record
Conditions
Obesity, Diabetes, Cardiovascular Diseases
Interventions
Whole milk, Nonfat milk
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity

NCT07876531
View directory record Official record
Conditions
Overweight and/or Obesity, Healthy Participants
Interventions
Berobenatide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

NCT07224399
View directory record Official record
Conditions
Healhty, Overweight or Obesity
Interventions
BGM1812, Placebo
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

NCT04839393
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

NCT06714955
View directory record Official record
Conditions
Non-diabetic Overweight or Obese
Interventions
Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

NCT05406115
View directory record Official record
Conditions
Obesity
Interventions
AMG 786, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Aventura, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

NCT03385369
View directory record Official record
Conditions
Safety, Healthy Subjects
Interventions
MEDI0382, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 29, 2026, 1:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

NCT04599478
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 29, 2026, 1:37 PM EDT